Interindividual Variability in Cytochrome P450 3A and 1A Activity Influences Sunitinib Metabolism and Bioactivation-Reference-Cited by-同舟云学术

Interindividual Variability in Cytochrome P450 3A and 1A Activity Influences Sunitinib Metabolism and Bioactivation

Published:2022-04-28 Issue:5 Volume:35 Page:792-806
ISSN:0893-228X
Container-title:Chemical Research in Toxicology
language:en
Short-container-title:Chem. Res. Toxicol.

Author:

Burnham Elizabeth A.¹,Abouda Arsany A.¹,Bissada Jennifer E.¹,Nardone-White Dasean T.²,Beers Jessica L.²^ORCID,Lee Jonghwa²,Vergne Matthew J.¹^ORCID,Jackson Klarissa D.²^ORCID

Affiliation:

1. Department of Pharmaceutical Sciences, Lipscomb University College of Pharmacy and Health Sciences, Nashville, Tennessee 37204, United States

2. Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina at Chapel Hill Eshelman School of Pharmacy, Chapel Hill, North Carolina 27599, United States

Funder

National Cancer Institute

National Institute of General Medical Sciences

Publisher

American Chemical Society (ACS)

Subject

Toxicology,General Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.chemrestox.1c00426

Reference63 articles.

1. Approval Summary: Sunitinib for the Treatment of Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors and Advanced Renal Cell Carcinoma

2. Sunitinib: From Rational Design to Clinical Efficacy

3. FDA. Sunitinib prescribing information, 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021938s037lbl.pdf.

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metabolic transformation of cyclopiazonic acid in liver microsomes from different species based on UPLC-Q/TOF-MS;Journal of Hazardous Materials;2024-09

2. Strategy for Cysteine-Targeting Covalent Inhibitors Screening using In-house Database based LC-MS/MS and Drug Repurposing;Journal of Pharmaceutical Analysis;2024-07

3. A Review of CYP-Mediated Drug Interactions: Mechanisms and In Vitro Drug-Drug Interaction Assessment;Biomolecules;2024-01-12

4. Preclinical evaluation of an 18F-labeled Nε-acryloyllysine piperazide for covalent targeting of transglutaminase 2;EJNMMI Radiopharmacy and Chemistry;2024-01-02

5. Integrating network pharmacology and drug side-effect data to explore mechanism of liver injury-induced by tyrosine kinase inhibitors;Computers in Biology and Medicine;2024-01